Current Preclinical Models for the Advancement of Translational Bladder Cancer Research

被引：25

作者：

DeGraff, David J. ^{[1
]}

Robinson, Victoria L. ^{[2
]}

Shah, Jay B. ^{[3
]}

Brandt, William D. ^{[4
]}

Sonpavde, Guru ^{[5
]}

Kang, Yibin ^{[6
]}

Liebert, Monica ^{[7
]}

Wu, Xue-Ru ^{[8
]}

Taylor, John A., III ^{[9
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[2] Univ Chicago, Chicago, IL 60637 USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Johns Hopkins Univ, Baltimore, MD USA

[5] Univ Alabama Birmingham, Birmingham, AL USA

[6] Princeton Univ, Princeton, NJ 08544 USA

[7] Soc Clin & Translat Sci, Washington, DC USA

[8] NYU, New York, NY USA

[9] Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 02期

关键词：

TRANSITIONAL-CELL-CARCINOMA; GROWTH-FACTOR RECEPTOR; HUMAN UROTHELIAL CELLS; URINARY-BLADDER; IN-VIVO; HA-RAS; ORTHOTOPIC MODELS; CULTURE MODEL; GENE-TRANSFER; MOUSE MODEL;

D O I：

10.1158/1535-7163.MCT-12-0508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care. Mol Cancer Ther; 12(2); 121-30. (C)2012 AACR.

引用

页码：121 / 130

页数：10

共 112 条

[1] SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation [J].